MedWire News: Results from an observational study of elderly Medicare beneficiaries in the USA show that rosiglitazone treatment is associated with an increased risk for cardiovascular disease (CVD) events compared with treatment with pioglitazone.
MedWire News: Results from an observational study of elderly Medicare beneficiaries in the USA show that rosiglitazone treatment is associated with an increased risk for cardiovascular disease (CVD) events compared with treatment with pioglitazone.